** Shares of drug developer ARS Pharmaceuticals rise ~4.8% to $8.44 premarket
** Co says European Medicines Agency (EMA) has recommended approval of its needle-free emergency treatment, EURneffy, for allergic reactions
** ARS says European Commission, which usually follows EMA's recommendation, is expected to decide on EURneffy in Q3 2024
** The nasal spray is also under review by U.S. Food and Drug Administration; expected make its decision on Oct. 2
** Up to last close, stock up 46.9% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments